TORONTO, May 16, 2026 (GLOBE NEWSWIRE) — VVC Exploration Corporation, dba VVC Resources (“VVC” or the “Company”) (TSX-V: VVC and OTCQB: VVCVF) announces that it has applied to the Ontario Securities Commission (the “OSC”), as its principal regulator, for a Management Cease Trade Order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). This application follows an anticipated delay in filing the Company’s audited annual financial statements, management’s discussion and analysis, and related officer certifications for the fiscal year ended January 31, 2026 (collectively, the “Required Filings”), which are due on June 1, 2026. Reason for Anticipated DefaultThe delay in completing the Required Filings is a direct result of recent material corporate...

LONDON, May 16, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (NYSE:NVT) (“nVent”), a global leader in electrical connection and protection solutions, today announced that its Board of Directors has approved a 3-year share repurchase program pursuant to which the Company may repurchase up to $500 million of nVent shares effective on July 23, 2026. The program is in addition to nVent’s existing authorization approved in July 2024, which expires July 23, 2027. nVent has approximately $96 million remaining under the July 2024 authorization. As of March 31, 2026, the company had approximately 162 million common shares outstanding. The authorization does not constitute a commitment to repurchase shares. The Company may conduct the repurchases through open market purchases, block trades and unsolicited negotiated transactions, pursuant...

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy Phase 3 head-to-head trial of the high-dose fianlimab combination versus Opdualag® (nivolumab and relatlimab-rmbw) is ongoing TARRYTOWN, N.Y., May 15, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today reviewed results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma. The trial did not reach statistical significance for the primary endpoint of improvement in progression-free...

VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company”) announces that it has entered into a service agreement with Market IQ Media Group Incorporated and Market IQ Media Group Limited (together “Market IQ”) dated May 11, 2026 (the “Agreement”), pursuant to which Market IQ will provide a comprehensive digital marketing campaign for a total cost of US$200,000 commencing on May 11, 2026. Under the terms of the Agreement, Market IQ will provide search engine optimization (“SEO”), targeted distribution across major search engines and financial media platforms, multimedia services, digital campaign optimization and analytics reporting. The campaign will continue for a period of (6) months until the allocated budget is fully deployed, with the...